Study Title
Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas (Bretuximab) (NCT02388490)

Trial description
This is an open-label, non-randomized, multi-center, phase II trial of brentuximab vedotin (also known as SGN-035) to evaluate ORR primarily in patients with Epstein-Barr virus (EBV)- and CD30-positive lymphomas.

This trial is sponsored by Seoul National University Hospital. [1]

Study data

  • Condition: Lymphoma
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 25
  • Start: April 2015
  • Estimated Completion: June 2017
  • Last verified: March 2015

Study Schematic

(Coming soon)

Last Editorial review: July 2, 2015
Information based on (NIH/NCI) and other sources.